Does de skull have bone marrow

Reading File

Finding Sources

Reading File

Yes, the skull does contain bone marrow.

Here's a concise breakdown:

Bone Marrow in the Skull

Yes — the skull is a flat bone and contains red (hematopoietic) bone marrow throughout life.

Structure

The skull bones (calvaria) have a "sandwich" structure:

Outer table — compact cortical bone
Diploe — the middle layer of spongy/cancellous bone between the two cortical tables. This is where red bone marrow resides.
Inner table — compact cortical bone

Role in Blood Cell Production

After birth, active blood cell production (hematopoiesis) initially occurs in all bones. As childhood progresses, hematopoiesis retreats to the flat bones — including the skull, vertebrae, ribs, sternum, shoulder girdle, and pelvis — and the proximal ends of the long bones. In adults, these flat bones remain the primary sites of red marrow and active blood cell production.

"Later in childhood, only the flat bones (the skull, vertebrae, thoracic cage, shoulder, and pelvis) and the proximal parts of the long bones... are sites of blood cell [production]." — Henry's Clinical Diagnosis and Management by Laboratory Methods

Clinical Relevance

In chronic hemolytic anemias (e.g., thalassemia, sickle cell disease), the demand for red blood cell production is so high that the skull marrow expands dramatically, eroding cortical bone and causing new bone formation — producing the classic "hair-on-end" appearance on skull X-rays.
Multiple myeloma classically causes punched-out lytic lesions in the skull, visible on lateral skull X-rays, because malignant plasma cells replace the normal marrow in the diploe.

So in short: the skull's diploe is a normal, lifelong site of red bone marrow and active hematopoiesis.

Why do we have to check eGFR before a patient takes MRI

Checking Date & Time

Finding Sources

Reading File

Loading Image

Finding Sources

Great — I have everything needed. Here's a clear explanation:

Why eGFR Must Be Checked Before MRI

The concern is not about the MRI itself — the magnetic field is safe for kidneys. The issue is about the gadolinium-based contrast agent (GBCA) that is often injected to enhance the MRI images.

The Risk: Nephrogenic Systemic Fibrosis (NSF)

When a patient with severely reduced kidney function (eGFR < 30 mL/min/1.73m²) receives gadolinium contrast, the kidneys cannot clear it quickly. The gadolinium ion can dissociate from its chelating ligand during this prolonged retention. Free gadolinium is toxic and triggers NSF — a rare but serious and potentially fatal condition characterized by:

Progressive hardening and thickening of the skin (scleroderma-like)
Fibrosis of internal organs (lungs, heart, liver, skeletal muscle)
Joint contractures and severe disability
No effective treatment once established

"One of the key concerns with gadolinium contrast is triggering nephrogenic systemic fibrosis (NSF) when the contrast is administered to patients with reduced kidney function. This is thought to be due to gadolinium ions dissociating from their ligand when clearance is reduced." — National Kidney Foundation Primer on Kidney Diseases, 8e

eGFR Thresholds

eGFR	Risk Level	Recommendation
> 30 mL/min	Low	GBCA generally safe (Group II agents)
< 30 mL/min	High	GBCA contraindicated or use with extreme caution
Dialysis / ESRD	Very High	Avoid; if unavoidable, dialyze promptly after

Not All Gadolinium Agents Are Equal

Modern guidelines stratify agents into groups:

Group	Risk	Examples
Group I (linear/older)	Highest — most NSF cases	Gadodiamide, Gadopentetate dimeglumine
Group II (macrocyclic/newer)	Very low — few or no confirmed NSF cases	Gadobutrol, Gadoteridol, Gadoterate meglumine
Group III	Unknown — treated as Group I out of caution	Gadoxetate disodium

Group II (macrocyclic) agents have a much more stable ring structure, so the gadolinium ion is less likely to dissociate — dramatically reducing NSF risk. Most modern radiology departments now use Group II agents almost exclusively.

"The risk of NSF is higher with group I (linear) agents and lower with newer group II (cyclic) agents." — Comprehensive Clinical Nephrology, 7th Edition

Key Takeaway

The eGFR check before MRI is essentially a pre-contrast safety screen. If the patient's kidneys work well enough to clear gadolinium promptly, NSF risk is negligible. If eGFR is < 30, the radiologist must either:

Use a Group II agent at the lowest possible dose, or
Avoid contrast entirely and perform an unenhanced MRI

Note: If the MRI is being done without contrast, there is no need to check eGFR for NSF reasons — the magnet itself poses no renal risk.

This is a shared conversation. Sign in to Orris to start your own chat.